ZYDUS LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of ZYDUS LIFESCIENCES have increased by 18.90% YoY .
The Earnings Per Share (EPS) of ZYDUS LIFESCIENCES has increased by 11.36 % YoY. |
||
ZYDUS LIFESCIENCES Last 5 Annual Financial Results
[BOM: 532321|NSE : ZYDUSLIFE]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹23,242 Cr | ₹19,547 Cr | ₹17,237 Cr | ₹15,110 Cr | ₹14,404 Cr |
| Expenses | ₹16,348 Cr | ₹14,248 Cr | ₹13,666 Cr | ₹11,935 Cr | ₹11,018 Cr |
| Operating Profit (Excl OI) | ₹6,894 Cr | ₹5,299 Cr | ₹3,572 Cr | ₹3,175 Cr | ₹3,385 Cr |
| Other Income | ₹460 Cr | ₹369 Cr | ₹475 Cr | ₹391 Cr | ₹75 Cr |
| Interest | ₹191 Cr | ₹81 Cr | ₹130 Cr | ₹127 Cr | ₹186 Cr |
| Depreciation | ₹916 Cr | ₹764 Cr | ₹723 Cr | ₹713 Cr | ₹670 Cr |
| Profit Before Tax | ₹6,027 Cr | ₹4,809 Cr | ₹2,590 Cr | ₹2,838 Cr | ₹2,399 Cr |
| Profit After Tax | ₹4,615 Cr | ₹3,831 Cr | ₹2,002 Cr | ₹2,326 Cr | ₹2,206 Cr |
| Consolidated Net Profit | ₹4,526 Cr | ₹3,860 Cr | ₹1,960 Cr | ₹4,487 Cr | ₹2,134 Cr |
| Earnings Per Share (Rs) | ₹50.10 | ₹44.99 | ₹38.36 | ₹19.37 | ₹43.82 |
| PAT Margin (%) | 9.73 | 10.10 | 10.10 | 5.90 | 7.87 |
| ROE(%) | 19.69 | 21.08 | 20.52 | 11.60 | 15.51 |
| ROCE(%) | 21.39 | 26.06 | 24.90 | 13.64 | 15.30 |
| Total Debt/Equity(x) | 0.43 | 0.13 | 0.04 | 0.07 | 0.25 |
Key Financials |
||
| Market Cap | : | ₹ 118,712.5 Cr |
| Revenue (TTM) | : | ₹ 30,378.1 Cr |
| Net Profit(TTM) | : | ₹ 4,159.0 Cr |
| EPS (TTM) | : | ₹ 41.7 |
| P/E (TTM) | : | 28.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ZYDUS LIFESCIENCES | -0.5% | 4.5% | 29.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.9% | 7.8% | 13% |
| DIVIS LABORATORIES | 11.5% | 20.6% | 68% |
| TORRENT PHARMACEUTICALS | 1% | 1.8% | 34.3% |
| CIPLA | 1.1% | 7.9% | -6.3% |
| DR REDDYS LABORATORIES | 1.1% | 11.8% | 14.9% |
| MANKIND PHARMA | 5.7% | 10.8% | 15.2% |
| LUPIN | 1.7% | 3.9% | 2.9% |
| AUROBINDO PHARMA | 2.1% | 7.2% | 62.2% |
ZYDUS LIFESCIENCES Revenues
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 18.90 % |
| 5 Yr CAGR | 12.71 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹23,242 Cr | 18.90 | |
| Mar2025 | ₹19,547 Cr | 13.40 | |
| Mar2024 | ₹17,237 Cr | 14.08 | |
| Mar2023 | ₹15,110 Cr | 4.90 | |
| Mar2022 | ₹14,404 Cr | - | |
ZYDUS LIFESCIENCES Operating Profit
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 30.09 % |
| 5 Yr CAGR | 19.46 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹6,894 Cr | 30.09 | |
| Mar2025 | ₹5,299 Cr | 48.35 | |
| Mar2024 | ₹3,572 Cr | 12.51 | |
| Mar2023 | ₹3,175 Cr | -6.22 | |
| Mar2022 | ₹3,385 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 9.41 % |
| 5 Yr CAGR | 5.99 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 29.66% | 9.41 | |
| Mar2025 | 27.11% | 30.84 | |
| Mar2024 | 20.72% | -1.38 | |
| Mar2023 | 21.01% | -10.60 | |
| Mar2022 | 23.5% | - | |
ZYDUS LIFESCIENCES Profit After Tax
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 17.26 % |
| 5 Yr CAGR | 20.68 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹4,526 Cr | 17.26 | |
| Mar2025 | ₹3,860 Cr | 96.88 | |
| Mar2024 | ₹1,960 Cr | -56.31 | |
| Mar2023 | ₹4,487 Cr | 110.32 | |
| Mar2022 | ₹2,134 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -3.66 % |
| 5 Yr CAGR | 5.45 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 9.73 % | -3.66 | |
| Mar2025 | 10.1 % | 0.00 | |
| Mar2024 | 10.1 % | 71.19 | |
| Mar2023 | 5.9 % | -25.03 | |
| Mar2022 | 7.87 % | - | |
ZYDUS LIFESCIENCES Earnings Per Share (EPS)
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 11.36 % |
| 5 Yr CAGR | 3.40 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹50 | 11.36 | |
| Mar2025 | ₹45 | 17.28 | |
| Mar2024 | ₹38 | 98.04 | |
| Mar2023 | ₹19 | -55.80 | |
| Mar2022 | ₹44 | - | |
ZYDUS LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | -17.92 % |
| 5 Yr CAGR | 8.74 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 21.39% | -17.92 | |
| Mar2025 | 26.06% | 4.66 | |
| Mar2024 | 24.9% | 82.55 | |
| Mar2023 | 13.64% | -10.85 | |
| Mar2022 | 15.3% | - | |
ZYDUS LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹1,190.1 |
| Current MarketCap | : | ₹ 118,712.5 Cr |
| Updated EOD on | : | Nov 11,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ZYDUS LIFESCIENCES | -0.5% |
4.5% |
29.6% |
| SENSEX | 5.9% |
13% |
-1.9% |
ZYDUS LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 200 | 4.8% | 10% | -0.3% |
| BSE 250 LARGEMIDCAP INDEX | 4.7% | 9.7% | 0.1% |
| BSE 500 | 4.5% | 8.8% | 0.2% |
| BSE 1000 | 4.3% | 8.1% | 0.6% |
| BSE HEALTHCARE | 3.7% | 8.5% | 18.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 5.3% | 10.8% | 28.8% |
| NIFTY 100 | 5.1% | 11.3% | -0.3% |
| NIFTY 200 | 4.8% | 10% | 0.2% |
| NIFTY 500 | 4.4% | 8.8% | 0.4% |
| NIFTY TOTAL MARKET | 4.4% | 8.4% | 0.8% |
You may also like the below Video Courses
FAQ about ZYDUS LIFESCIENCES Financials
How the annual revenues of ZYDUS LIFESCIENCES have changed ?
The Revenues of ZYDUS LIFESCIENCES have increased by 18.90% YoY .
How the Earnings per Share (EPS) of ZYDUS LIFESCIENCES have changed?
The Earnings Per Share (EPS) of ZYDUS LIFESCIENCES has increased by 11.36 % YoY .
Check out Intrinsic Value of Peers of ZYDUS LIFESCIENCES
Compare Stock Analytics of Peers of ZYDUS LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
